Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma

Jason Luke, MD
Published Online: Friday, Nov 10, 2017



Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

The future of systemic therapy for patients with melanoma in the advanced stages is in combinations, explains Luke. Currently, the standard of care for many patients is PD-1 antibodies, but combinations will continue to show improvement.

Combinations are also showing improvement in the adjuvant setting. In the next 2 to 5 years, most patients will be receiving combinations, states Luke.



Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

The future of systemic therapy for patients with melanoma in the advanced stages is in combinations, explains Luke. Currently, the standard of care for many patients is PD-1 antibodies, but combinations will continue to show improvement.

Combinations are also showing improvement in the adjuvant setting. In the next 2 to 5 years, most patients will be receiving combinations, states Luke.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x